As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...

SHANGHAI, Sept. 11, 2019 /PRNewswire/ -- According to Morgan Stanley Capital International's (MSCI) latest set of ESG ratings, 3SBio has been upgr ...

3SBio is a leading biotech drugmaker in China. It is one of the earliest biologics innovators in the country, launching EPIAO in 1998 and TPIAO in 2005, which are market-leading innovative drugs ...

NuLeusin, 3SBio’s second generation IL-2 drug, would essentially be a new market for 3SBio (the company does have a legacy IL-2 product, but its sales are negligible).

3SBio Inc., (HKEX:1530) ("3SBio" or 'the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, ...

3SBio is a leading biopharmaceutical company in China. It is one of the earliest biologics innovators in the country, launching EPIAO in 1998 and TPIAO in 2005. The current portfolio is older ...

SHANGHAI, Sept. 11, 2019 /PRNewswire/ -- According to Morgan Stanley Capital International's (MSCI) latest set of ESG ratings, 3SBio has been upgraded to BBB status, surpassing that of 61% of ...